Pathology & Oncology Research

, Volume 25, Issue 1, pp 401–408 | Cite as

Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze

  • Hatice ToyEmail author
  • Ozlem Etli
  • Zeliha Esin Celik
  • Arsenal Sezgin Alikanoglu
Original Article


This study aimed to evaluate the morphometric measurements in cases with papillary thyroid carcinoma, and determine a cut-off value to support diagnosis. Fifty cases with a diagnosis of papillary thyroid carcinoma (PTC) were included in the study with their Galectine-3, CK-19 and HBME-1 immunohistochemical staining results. Demographic and clinical data gathered from pathology reports, which included demographic information such as patients’ sex, age, macroscopic tumor size, number of tumor focuses; prognostic parameters such as lenfovascular invasion, perineural invasion, thyroid capsule invasion; and results of immunohistochemical CK- 19, Galectin-3 and HBME-1 staining. Longest nuclear diameters of 150 tumor cells and 150 normal thyrocytes of each case were manually measured in an image analysis software, and mean longest nuclear diameters (MLND-TC and MLND-NC), and also tumor cell/normal cell longest nuclear diameter ratio (TC/NC-LNDR) were calculated. MLND-TC was higher than MLND-NC. The cases with higher MLND-TC had increased risk of capsule invasion in case of a negative staining with Galectine-3, HBME-1, or CK-19. When TC/NC-LNDR was high, number of tumor focus tended to be multiple and lymphovascular invasion risk was also increased. Subtypes of PTC were not differed regarding staining patterns. And finally, increased TC/NC-LNDR was associated with increased risk of having poor prognostic factors. The results of this study suggest that MLND-NC, MLND-TC, and TC/NCLNDR are valuable and easy-to-use measures, which can assist routine histology practice.


Papillary thyroid carcinoma Nucleus diameter Morphometric analyze 


  1. 1.
    Cheung CC et al (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14(4):338–342CrossRefGoogle Scholar
  2. 2.
    Coli A et al (2002) Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 40(1):80–87CrossRefGoogle Scholar
  3. 3.
    Collan Y (1986) Diagnostic morphometry: relevant background to decision-making in diagnostic histopathology. In: In Science of Form: Proceedings of the First International Symposium for Science on Form 1986, KTK Scientific Publishers, Tokyo, p. 533-542Google Scholar
  4. 4.
    Isic Dencic T et al (2013) Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol 30(1):362CrossRefGoogle Scholar
  5. 5.
    Kefeli M et al (2010) Morphometric analysis in cytologic evaluation of papillary thyroid carcinoma. Anal Quant Cytol Histol 32(4):234–238Google Scholar
  6. 6.
    Kumar V, et al (2014) Robbins and cotran pathologic basis of disease – 2014. Online: ElsevierHealth SciencesGoogle Scholar
  7. 7.
    Kuzey G (2007) Temel Patoloji, 1st edn. Gunes Kitabevi, İstanbulGoogle Scholar
  8. 8.
    Lee TK et al (1987) The significance of nuclear diameter in the biologic behavior of thyroid carcinomas: a retrospective study of 127 cases. Hum Pathol 18(12):1252–1256CrossRefGoogle Scholar
  9. 9.
    Lee KJ et al (2011) Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg 35(2):318–323CrossRefGoogle Scholar
  10. 10.
    Liu Z et al (2014) Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med 7(8):2304–2308Google Scholar
  11. 11.
    Mai KT et al (2002) Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40(2):133–142CrossRefGoogle Scholar
  12. 12.
    de Matos PS et al (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47(4):391–401CrossRefGoogle Scholar
  13. 13.
    Mills SE (2004) Sternberg’s diagnostic surgical pathology, vol 1, 4th edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  14. 14.
    Nagashima T, Suzuki M, Nakajima N (1997) Cytologic morphometric approach for the prediction of lymph node involvement in papillary thyroid cancer. Anal Quant Cytol Histol 19(1):49–54Google Scholar
  15. 15.
    Saggiorato E et al (2001) Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86(11):5152–5158CrossRefGoogle Scholar
  16. 16.
    Salmon I et al (1992) Comparison of morphonuclear features in normal, benign neoplastic thyroid tissue by digital cell image analysis. Anal Quant Cytol Histol 14(1):47–54Google Scholar
  17. 17.
    Schlumberger MJ (2004) Papillary thyroid carcinoma. Orphanet Encyclopedia. Accessed 16 Nov 2017
  18. 18.
    Seok JY, et al (2015) Prognostic value of HBME - 1 in papillary thyroid carcinoma. In: 15th Congress of the Asian Association of Endocrine Surgeons. Seoul, KoreaGoogle Scholar
  19. 19.
    Sorensen FB (1992) Quantitative analysis of nuclear size for objective malignancy grading: a review with emphasis on new, unbiased stereologic methods. Lab Investig 66(1):4–23Google Scholar
  20. 20.
    Wallander M et al (2010) Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. Appl Immunohistochem Mol Morphol 18(3):231–235CrossRefGoogle Scholar
  21. 21.
    Weber KB et al (2004) The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–531CrossRefGoogle Scholar
  22. 22.
    Wu G et al (2013) Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity? J Int Med Res 41(4):975–983CrossRefGoogle Scholar
  23. 23.
    Zink D, Fischer AH, Nickerson JA (2004) Nuclear structure in cancer cells. Nat Rev Cancer 4(9):677–687CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Hatice Toy
    • 1
    Email author
  • Ozlem Etli
    • 2
  • Zeliha Esin Celik
    • 3
  • Arsenal Sezgin Alikanoglu
    • 4
  1. 1.Medicine Faculty, Department of PathologyNecmettin Erbakan University MeramKonyaTurkey
  2. 2.Department of PathologyPendik State HospitalIstanbulTurkey
  3. 3.Medicine Faculty, Department of PathologySelcuk UniversityKonyaTurkey
  4. 4.Department of PathologyAntalya Education and Research HospitalAntalyaTurkey

Personalised recommendations